Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis

[1]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[2]  K. Narayan,et al.  Health consequences of early-onset compared with late-onset type 2 diabetes mellitus , 2022, Precision clinical medicine.

[3]  Longyan Yang,et al.  Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment , 2022, Molecules.

[4]  E. Huang,et al.  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[5]  P. Sumithran,et al.  Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation , 2021, The Lancet.

[6]  T. Jafar,et al.  Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry , 2021, PloS one.

[7]  W. Kaewput,et al.  National trends in the prevalence of glycemic control among patients with type 2 diabetes receiving continuous care in Thailand from 2011 to 2018 , 2021, Scientific Reports.

[8]  O. Nerman,et al.  Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88 , 2021, Diabetes Care.

[9]  J. Coresh,et al.  Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. , 2021, The New England journal of medicine.

[10]  S. Kuo,et al.  Association of Renal and Cardiovascular Safety With DPP‐4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease , 2021, Clinical pharmacology and therapeutics.

[11]  A. Kong,et al.  Trends in Glucose-Lowering Drug Use, Glycemic Control, and Severe Hypoglycemia in Adults With Diabetes in Hong Kong, 2002–2016 , 2020, Diabetes Care.

[12]  F. Hu,et al.  Nearly a decade on — trends, risk factors and policy implications in global obesity , 2020, Nature Reviews Endocrinology.

[13]  Y. Saisho.  SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes? , 2020, Diseases.

[14]  Michael Fang.  Trends in Diabetes Management Among US Adults: 1999–2016 , 2020, Journal of General Internal Medicine.

[15]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[16]  A. Farmer,et al.  Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017 , 2019, Diabetes, obesity & metabolism.

[17]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[18]  T. Wascher,et al.  „Diabesity“ – Adipositas und Typ-2-Diabetes (Update 2019) , 2019, Wiener klinische Wochenschrift.

[19]  W. Rathmann,et al.  Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016) , 2018, Postgraduate medicine.

[20]  Marc J Gunter,et al.  Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment , 2018, The lancet. Diabetes & endocrinology.

[21]  H. Anders,et al.  CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease , 2018, Nature Reviews Nephrology.

[22]  Chung-Yi Li,et al.  Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second‐ and third‐line antidiabetic drugs in patients with type 2 diabetes , 2017, British journal of clinical pharmacology.

[23]  G. Bray,et al.  Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. , 2016, The lancet. Diabetes & endocrinology.

[24]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[25]  Tran Quoc Bao,et al.  Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants , 2016, The Lancet.

[26]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations , 2016, Obesity Surgery.

[27]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[28]  Kevin Hall,et al.  Management of obesity: improvement of health-care training and systems for prevention and care , 2015, The Lancet.

[29]  B. Swinburn,et al.  Strengthening of accountability systems to create healthy food environments and reduce global obesity , 2015, The Lancet.

[30]  Richard Horton,et al.  Rethinking and reframing obesity , 2015, The Lancet.

[31]  Ross A. Hammond,et al.  Smart food policies for obesity prevention , 2015, The Lancet.

[32]  Boyd Swinburn,et al.  Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking , 2015, The Lancet.

[33]  P. Lee,et al.  Predictors of poor glycaemic control in older patients with type 2 diabetes mellitus. , 2015, Singapore medical journal.

[34]  J. Ioannidis,et al.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.

[35]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[36]  J. Coresh,et al.  Trends in Prevalence and Control of Diabetes in the United States, 19881994 and 19992010 , 2014, Annals of Internal Medicine.

[37]  D. Wu,et al.  Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis , 2014, Diabetes, obesity & metabolism.

[38]  De-Min Yu,et al.  Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables , 2013, BMC Public Health.

[39]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[40]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[41]  E. Riboli,et al.  Can Noncommunicable Diseases Be Prevented? Lessons from Studies of Populations and Individuals , 2012, Science.

[42]  Jin-kui Yang,et al.  Management status of type 2 diabetes mellitus in tertiary hospitals in Beijing: gap between guideline and reality. , 2012, Chinese medical journal.

[43]  M. Ezzati,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[44]  A. Rudich,et al.  Adolescent BMI trajectory and risk of diabetes versus coronary disease. , 2011, The New England journal of medicine.

[45]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[46]  W. Fakhoury,et al.  A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes , 2010, Pharmacology.

[47]  J. Chan,et al.  Multifaceted Determinants for Achieving Glycemic Control , 2009, Diabetes Care.

[48]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[49]  Parvez Hossain,et al.  Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.

[50]  C. Ezenwaka,et al.  Differences in cardiovascular disease risk factors in elderly and younger patients with type 2 diabetes in the West Indies. , 2002, Singapore medical journal.

[51]  M. Franz,et al.  The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.

[52]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[53]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[54]  E. A. Sims,et al.  Endocrine and metabolic effects of experimental obesity in man. , 1973, Recent progress in hormone research.